Editas Medicine (EDIT) Equity Average (2016 - 2025)

Editas Medicine (EDIT) has 10 years of Equity Average data on file, last reported at $20.4 million in Q4 2025.

• Quarterly Equity Average fell 86.85% year-over-year to $20.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $20.4 million (down 86.85% YoY) and the FY2025 annual result came in at $80.8 million, down 66.58% from the prior year.
• Equity Average advanced to $20.4 million in Q4 2025 per EDIT's latest filing, from $16.3 million in the prior quarter.
• Across five years, Equity Average topped out at $625.7 million in Q2 2021 and bottomed at $16.3 million in Q3 2025.
• The 5-year median for Equity Average is $356.7 million (2023), against an average of $335.7 million.
• The widest annual swing landed in 2021, when Equity Average surged 107.56%; it then sank 91.99% in 2025.
• Tracing EDIT's Equity Average over 5 years: stood at $570.2 million in 2021, then slumped by 32.01% to $387.7 million in 2022, then declined by 8.49% to $354.8 million in 2023, then sank by 56.32% to $155.0 million in 2024, then sank by 86.85% to $20.4 million in 2025.
• Per Business Quant, the three latest EDIT Equity Average figures stand at $20.4 million (Q4 2025), $16.3 million (Q3 2025), and $40.8 million (Q2 2025).

Peer Comparison